Form 4: Alkermes EVP Exercises Options, Sells Shares

Alkermes' EVP of R&D and Chief Medical Officer, Craig C. Hopkinson, exercised stock options and subsequently sold a portion of his shares under a pre-arranged 10b5-1 trading plan.

Summary

• Craig C. Hopkinson, EVP R&D and Chief Medical Officer of Alkermes plc, exercised 5,000 employee stock options at an exercise price of $19.34 per share on April 1, 2026.
• Following the option exercise, Mr. Hopkinson directly owned 94,389 Ordinary Shares.
• On the same date, Mr. Hopkinson sold 9,000 Ordinary Shares at a weighted average price of $35.5116 per share, with prices ranging from $35.50 to $35.62.
• Both the option exercise and the subsequent sale were conducted pursuant to a Rule 10b5-1 trading plan adopted on March 14, 2025.
• After these transactions, Mr. Hopkinson's direct beneficial ownership of Ordinary Shares stands at 85,389.
• He also retains 16,356 unexercised employee stock options, which are fully vested and expire on February 22, 2031.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While an executive sold shares, it was part of a pre-planned 10b5-1 program, which mitigates concerns about negative insider sentiment.

Positives

• The exercise of options at $19.34 allowed the executive to acquire shares significantly below the market sale price of $35.5116.
• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned liquidity event rather than a reaction to new, non-public information.

Negatives

• The sale of 9,000 Ordinary Shares by a key executive reduces their direct equity stake in the company.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under Rule 10b5-1 plans, are common practice for executives managing their equity compensation and personal finances. These pre-scheduled sales generally carry less signaling weight regarding the company's immediate prospects compared to unscheduled, discretionary sales.

Stakeholder Impact

• Shareholders: The sale by an executive could be perceived as a slight negative signal, though mitigated by the 10b5-1 plan.

Key Dates

Recommendation

The filing details a routine insider transaction involving an option exercise and subsequent share sale under a pre-established 10b5-1 plan. This type of transaction is generally not indicative of a change in the company's fundamental outlook or a strong signal for future stock performance, thus a 'hold' recommendation is appropriate as it doesn't provide new information to alter an existing investment thesis.

Keywords

Alkermes, ALKS, Form 4, Insider Trading, Stock Options, Share Sale, Executive Compensation, Rule 10b5-1, Craig C. Hopkinson